Training Seminars logo

Cambridge Healthtech Training Seminars offer real-life case studies, problems encountered and solutions applied, and extensive coverage of the basic science underlying each topic. Experienced Training Seminar instructors offer a mix of formal lectures, interactive discussions and activities to help attendees maximize their learning experiences. These immersive trainings will be of value to scientists from industry and academic research groups who are entering new fields – and to those working in supporting roles that will benefit from an in-depth briefing on a specific aspect of the industry.

Monday, Tuesday August 5-6, 2019


Introduction to Cancer Immunotherapy Discovery and Development 

Instructor: Dina Schneider, PhD, Associate Director, Translational Research, Lentigen Technology, a Miltenyi Biotec Company

This course will cover the recent advances in cancer immunotherapy discovery and development. Immune checkpoint inhibitors and CAR T therapies have recently gained regulatory approval in the US and the EU. TILs- and TCR -based therapies, as well as cancer vaccines are areas of great promise. Combination therapies are contributing to the clinical progress where single therapies fail. Advances in high throughput sequencing and immunogenomics aid in identifying novel tumor antigens, improving effector molecules and vaccines, and predicting clinical outcomes.

Topics include:

  • History of Immunotherapy
  • Monoclonal Antibodies
  • Checkpoint Blockade Inhibitors
  • CARs
  • TILs
  • TCRs
  • Cancer Vaccines
  • Combination Therapies
  • HTS and Immunogenomics
  • Clinical Progress to Date and Future Directions

Speaker Biography

Dina Schneider, PhD, Associate Director, Translational Research, Lentigen Technology, a Miltenyi Biotec Company
Dina Schneider, BSPharm, PhD, is a scientist and inventor with over 15 years of experience in academia and industry. Dr. Schneider earned her PhD from Michigan State University and did her postdoctoral training at the University of Michigan. Her academic career spanned diverse areas of interest, including cellular and molecular immunology, immunotoxicology, inflammation, and molecular biology. In 2011, Dr. Schneider transitioned to industry, where she contributed to numerous projects in synthetic immunology, immunotherapy, and chimeric antigen receptor (CAR) T cell-based therapy. Dr. Schneider leads the Translational Research group at Lentigen Technology, Inc., a Miltenyi Biotec Company, in Gaithersburg, MD. Her group is focused on pre-clinical development of novel CAR-based therapies targeting hematologic malignancies as well as solid tumors, and on the implementation of CliniMACS Prodigy® clinical platform for preparation of cell-based therapeutics. Her recent work includes the development of novel CAR therapies, three of which are now in the clinic.

What is a Training Seminar?
Each Training Seminar offers 1.5 Days of instruction with start and stop times for each day shown above and on the Event-at-a-Glance published in the onsite Program & Event Guide. Training Seminars will include morning and afternoon refreshment breaks, as applicable, and lunch will be provided to all registered attendees on the full day of the class.

Each person registered specifically for the training seminar will be provided with a hard copy handbook for the seminar in which they are registered. A limited number of additional handbooks will be available for other delegates who wish to attend the seminar, but after these have been distributed no additional books will be available.

Though CHI encourages track and symposia hopping between conference programs, we ask that Training Seminars not be disturbed once they have begun. In the interest of maintaining the highest quality learning environment for Training Seminar attendees, and because Seminars are conducted differently than conference programming, we ask that attendees commit to attending the entire program, and NOT engaging in track hopping, as to not disturb the hands-on style instruction being offered to the other participants.

Preliminary Agenda

Conference Programs